Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trials
Prostate cancer trial ended, metastatic breast cancer trial continues, company reports
November 17th, 2005
Kosan Biosciences (KOSN) announced that it has discontinued its phase 2 clinical trial of KOS-862 in hormone refractory prostate cancer (the KOS-202 trial). Although clinical activity was observed, based on the predefined criteria of the two-stage Simon trial design, the interim analysis of the data revealed that KOS-862 did not meet the trial's endpoint for the number of patients with a response to therapy, as measured by change in a tumor marker (prostate specific antigen--PSA) levels. The phase 2 monotherapy breast cancer clinical trial continues to enroll patients, and preliminary data have been accepted for presentation at the San Antonio Breast...
Source: Women's Health Weekly (2005-11-17)
|
